NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data

Key Takeaways Novo Nordisk and its partner reported phase II data for UBT251 in Chinese patients with type II diabetes.UBT251 showed up to a 2.16% HbA1c reduction and 9.8% weight loss, outperforming semaglutide and placebo.Novo Nordisk plans a global phase II in 2026, while its partner prepares for phase III trials in China.Novo Nordisk (NVO) and its partner, The United Laboratories International Holdings Limited ("TUL"), jointly announced top-line data from a phase II study in China, evaluating UBT251, a n ...